BioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing Cypath® Lung Sales
BioAffinity Technologies報告第二季度營業收入爲240萬美元,由於Cypath®肺部銷售的增長推動。
BioAffinity Technologies Reports $2.4 Million Revenue for Q2 Driven by Growing Cypath® Lung Sales
BioAffinity Technologies報告第二季度營業收入爲240萬美元,由於Cypath®肺部銷售的增長推動。
譯文內容由第三人軟體翻譯。